ICYMI: Private Equity-backed Anthos Therapeutics Announces Breakthrough Development in New Blood Clot Treatment
Recently, Anthos Therapeutics, a Massachusetts-based biopharmaceutical company supported by private equity announced at a meeting of the American Heart Association that their new drug demonstrated a potential to significantly reduce the risk of blood clots. Backed by AIC member Blackstone Life Sciences, this new treatment could provide a safer alternative for the 12.1 million Americans expected to suffer from atrial fibrillation by 2030.
The drug, abelacimab, cut the overall risk of bleeding by 67% when compared to the current standard of care used by patients. Overwhelming success in the latest round of testing encouraged researchers to end the trial early and the Food and Drug Administration has said it would fast-track its review of the treatment.
Blackstone Life Sciences recently released a new video discussing this innovative new breakthrough treatment. The American Investment Council also recently featured Anthos in our video series about how private equity is investing in medical technology that improves lives. Please click here to learn more or visit: investmentcouncil.org/healthcare/.
Notable media coverage of this exciting new breakthrough is included below:
- STAT: Anthos stroke drug appears safer than common blood thinner in mid-stage trial
- “Anthos, which is backed by Blackstone Life Sciences, licensed the drug from Novartis in 2019. The biotech is running three Phase 3 trials, one to study stroke prevention in people with atrial fibrillation, and the other two in people with cancer-associated vein blockages. The Food and Drug Administration has said it would fast-track its review of the treatment.”
- Endpoints: Anthos’ blood thinner cuts the risk of bleeding amid race to develop safer anticoagulants
- “In a Phase II study, Anthos’ abelacimab cut the risk of bleeding by 67% compared to Bayer and Johnson & Johnson’s widely used anticoagulant Xarelto in patients with atrial fibrillation. It also reduced the risk of major bleeding by 74% and the risk of gastrointestinal bleeding by 93%, according to trial results presented Saturday at the American Heart Association’s scientific meeting.”
- BioPharma Dive: Anthos blood thinner bests Xarelto on safety in mid-stage study
- “Abelacimab is one of a promising new class of anticoagulants known as a Factor XI or Factor XIa inhibitors. Bristol Myers Squibb and Bayer have bet big on Factor XIa inhibitors of their own, launching late-stage trial programs set to enroll tens of thousands of participants.”